SYL040012, Treatment for Open Angle Glaucoma

PHASE2CompletedINTERVENTIONAL
Enrollment

184

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

August 31, 2015

Study Completion Date

January 31, 2016

Conditions
Open Angle GlaucomaOcular Hypertension
Interventions
DRUG

1 drop of 0.375% SYL040012 (bamosiran)

DRUG

1 drop of 0.750% SYL040012 (bamosiran)

DRUG

1 drop of 1.125% SYL040012 (bamosiran)

DRUG

1 drop of 1.5% SYL040012 (bamosiran)

DRUG

1 drop of 0.5 % timolol maleate

Trial Locations (21)

10138

East Tallin Central Hospital, Tallinn

11407

Hospital de Jerez, Jerez de la Frontera

13419

Eye Clinic Dr. Krista Turman, Tallinn

28034

Hospital Universitario Ramón y Cajal, Madrid

28040

Hospital Universitario Clínico San Carlos, Madrid

30260

Eye Care Centers Management, Inc (Clayton Eye Center), Morrow

31008

Clinica Universidad Navarra, Pamplona

36001

Complejo Hospitalario de Pontevedra, Pontevedra

39106

University Clinic Magdeburg, Magdeburg

40217

Taustin Eye Center, Louisville

47011

Instituto de Oftalmobiología Aplicada, Valladolid

50009

Hospital Universitario Miguel Servet, Zaragoza

50406

Tartu University Hospital, Tartu

79106

Universitaetsklinikum Freiburg, Freiburg im Breisgau

80336

Klinikum der Universität München, München

90701

Sall Research Medical Center, Artesia

93053

University Hospital Regensburg, Regensburg

94954

North Bay Eye Associates, Petaluma

D-48149

Universitätsklinikum Münster, Münster

03186

Hospital de Torrevieja, Torrevieja

08036

Hospital Clinic, Barcelona

All Listed Sponsors
lead

Sylentis, S.A.

INDUSTRY

NCT02250612 - SYL040012, Treatment for Open Angle Glaucoma | Biotech Hunter | Biotech Hunter